Clean Science and Technology Limited — Investor Meet, 20-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Clean Science reported a resilient Q4 FY26 with standalone revenues at ₹193 Cr (up 8% QoQ, down 19% YoY) and consolidated revenues at ₹246 Cr (up 14% QoQ). Consolidated EBITDA was ₹96 Cr (33% margin), PAT ₹58 Cr (28% margin). Full-year standalone revenue was ₹796 Cr, consolidated ₹945 Cr.

HALS business showed strong traction, reaching over 1,000 tonnes volume in Q4, driven by exports. The company is backward integrating for HALS and debottlenecking lines. Hydroquinone/Catechol plant is stabilizing, replacing imports. Management noted a "tricky" FY27 due to global macro uncertainties and Chinese price competition. A final dividend of ₹4/share was declared. Management emphasizes efficiency and strategic expansion for long-term growth.